Timber Pharmaceuticals, Inc. (TMBR)
Market Open
28 Nov, 20:59
AMEX AMEX Primary $
0. 34
+0
+0.7351%
$
1.18M Market Cap
- P/E Ratio
- Div Yield
130,464 Volume
- Eps
$ 0.34
Previous Close Want to track TMBR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
TMBR trading today higher at $0.34, an increase of 0.7351% from yesterday's close, completing a monthly increase of 0% or $0.34. Over the past 12 months, TMBR stock gained 0%.
TMBR is not paying dividends to its shareholders.
The last earnings report, released on Aug 19, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Timber Pharmaceuticals, Inc. has completed 3 stock splits, with the recent split occurring on Nov 09, 2022.
The company's stock is traded on one exchange.
MSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sources
MSG Networks, the embattled cable TV station that airs New York Knicks and Rangers games, is in talks to reach a deal to avoid bankruptcy as soon as Friday.
Nypost | 1 year ago
Timber Pharmaceuticals, Inc. (TMBR) FAQ
What is the stock price today?
The current price is $0.34.
On which exchange is it traded?
Timber Pharmaceuticals, Inc. is listed on AMEX.
What is its stock symbol?
The ticker symbol is TMBR.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.18M.
Has Timber Pharmaceuticals, Inc. ever had a stock split?
Timber Pharmaceuticals, Inc. had 3 splits and the recent split was on Nov 09, 2022.
Timber Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | John Koconis CEO | AMEX Exchange | 887080208 CUSIP |
| US Country | 9 Employees | - Last Dividend | 19 May 2020 Last Split | - IPO Date |
Overview
Timber Pharmaceuticals LLC is a clinical-stage biopharmaceutical entity focused on advancing treatment options for patients with orphan dermatologic conditions. Established in 2019 and based in Basking Ridge, New Jersey, Timber Pharmaceuticals combines innovative research with a dedication to addressing the unmet medical needs in dermatology, specifically targeting rare genetic keratinization disorders and other specialized dermatologic conditions. Its strategic licensing agreements and partnerships, like the one with AFT Pharmaceuticals Limited, bolster its product development pipeline and potential market reach.
Products and Services
- TMB-001: A patented topical formulation of isotretinoin aimed at treating moderate to severe forms of congenital ichthyosis (CI), a rare genetic skin disorder. TMB-001 has successfully completed a Phase 2b clinical trial, marking a significant milestone in its development process. This product candidate represents Timber Pharmaceuticals' commitment to addressing severe dermatologic conditions through advanced topical therapies.
- TMB-002: This proprietary topical formulation of rapamycin is currently in Phase 2b clinical trials. It is designed for the treatment of facial angiofibroma in patients with tuberous sclerosis complex (TSC), a genetic condition that causes growths in various organs. TMB-002 reflects the company’s focus on providing novel treatments for complex genetic diseases with dermatologic manifestations.
- TMB-003: A novel formulation of Sitaxsentan, TMB-003 targets sclerotic skin diseases. Still in preclinical development, this selective endothelin-A receptor antagonist is Timber Pharmaceuticals' exploration into treating more systemic and potentially life-altering dermatologic conditions through targeted therapies.
- BPX-01: Currently in Phase 3 development, BPX-01 is a topical minocycline formulation aimed at treating inflammatory lesions caused by acne vulgaris. This product demonstrates Timber Pharmaceuticals' efforts in addressing common dermatologic issues with innovative, more effective treatments.
- BPX-04: A topical minocycline product, BPX-04 is Phase 3 ready and developed for the treatment of papulopustular rosacea. Its development underscores the company's commitment to expanding its dermatological treatments range, even further into chronic inflammatory skin diseases.
Contact Information
Address: 110 Allen Road
Phone: 973 314 9577
Website: https://www.timberpharma.com
